RPS6KB1 and small cell lung carcinoma: As a consequence of FGF2 stimulation, PKCε complex formation with BRAF and S6K2, but not with S6K1 and RAF-1, induced drug resistance in SCLC (small cell lung cancer) cells, HEK293 and U2OS cells (Figure 2) [100,102].